ZURA zurabio.com: Net earnings per share for the last 12 months

This price chart on the GURU.Markets platform, where the EPS is -76.30, highlights the costs Zura Bio Limited (ZURA) incurs for strict temperature control during sample transportation. Zura Bio Limited (ZURA) relies on the development of the unique ZB-168 antibody, capable of suppressing two inflammatory pathways, which provides significant pricing power. However, the business faces binary risks due to its narrow specialization in autoimmune pathologies without any commercial products.
Financial and market metric breakdowns for Zura Bio Limited (ZURA)

Investors in Zura Bio Limited (ZURA) must weigh current R&D expenditures against future capitalization potential. This indicator strips away accounting adjustments, measuring real net income dynamics over the year via the history of EPS YoY (ttm) percentage changes. The current value of -76.30 reflects the fundamental efficiency of capital management. For this developer of immunological drugs, this metric serves as a marker for the transition from clinical trial stages to commercial profitability.